Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $863000.0.

  • Crinetics Pharmaceuticals' Capital Expenditures rose 6344.7% to $863000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 6888.0%. This contributed to the annual value of $3.8 million for FY2024, which is 1800.34% down from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Capital Expenditures stood at $863000.0 for Q3 2025, which was up 6344.7% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Capital Expenditures ranged from a high of $3.5 million in Q3 2023 and a low of $18000.0 during Q4 2021
  • Moreover, its 5-year median value for Capital Expenditures was $613000.0 (2022), whereas its average is $838315.8.
  • Over the last 5 years, Crinetics Pharmaceuticals' Capital Expenditures had its largest YoY gain of 393636.36% in 2024, and its largest YoY loss of 8491.43% in 2024.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Capital Expenditures stood at $18000.0 in 2021, then surged by 1422.22% to $274000.0 in 2022, then soared by 241.24% to $935000.0 in 2023, then grew by 10.05% to $1.0 million in 2024, then dropped by 16.13% to $863000.0 in 2025.
  • Its Capital Expenditures was $863000.0 in Q3 2025, compared to $3.2 million in Q2 2025 and $1.2 million in Q1 2025.